Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall confidence in the ...
Alterity Therapeutics (ASX:ATH) CEO Dr David Stamler presented new analyses from the phase II double-blinded ATH434-201 trial in MSA, showing positive effects on slowing disease progression and ...
Alterity Therapeutics (ATHE) announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy ...
At least, that is what doctors thought the first day he was in the hospital in late June.
The MS for Dwyfor Meirionnydd hosts an event at the Senedd, urging greater support for rare diseases, especially in the Welsh ...
Could an anomaly in the developing brain explain motor difficulties occurring decades later in people with rare movement ...
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), today announced that it will be presenting two rapid-fire presentations at CHEST 2025, the annual meeting of the ...
CND Life Sciences, Inc. (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests and ...
On October 13, GemVax & KAEL announced that it held a plaque unveiling ceremony for the "International Progressive ...
Scottsdale, Arizona Thursday, October 9, 2025, 10:00 Hrs [IST] ...
Drawing correlations between sport and neurological conditions was once considered controversial, but multiple studies have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback